CSBio CSBio

X
[{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Announces Close of US$50 million \/ EUR42 million Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ExeVir Bio"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials.

            Lead Product(s): VHH72-Fc antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: XVR011

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: VIB

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing March 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY